KIT and neoplasm: As a multi-kinase angiogenesis inhibitor, sorafenib functions through the dual inhibition of Raf kinase signaling and receptor tyrosine kinase (RTK) autophosphorylation (VEGFR, PDGFR, c-Kit, RET), thereby suppressing tumor progression and vascular development.